Poseida Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value
Poseida Therapeutics, Inc. had Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value of $500.00 thousand as of 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 · last filed 2024-11-07
- 2024-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value $500.00K.
- 2024-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value $551.00K.
- 2024-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value $718.00K.
- 2023-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value $840.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value |
|---|---|
| 2024-09-30 | $500.00K 10-Q · filed 2024-11-07 |
| 2024-06-30 | $551.00K 10-Q · filed 2024-08-05 |
| 2024-03-31 | $718.00K 10-Q · filed 2024-05-14 |
| 2023-12-31 | $840.00K 10-K · filed 2024-03-07 |
| 2023-09-30 | $155.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | $22.00K 10-Q · filed 2023-08-08 |
| 2023-03-31 | $373.00K 10-Q · filed 2023-05-09 |
| 2022-12-31 | $2.40M 10-K · filed 2023-03-09 |
| 2022-09-30 | $619.00K 10-Q · filed 2022-11-10 |
| 2022-06-30 | $198.00K 10-Q · filed 2022-08-11 |
| 2022-03-31 | $1.33B 10-Q · filed 2022-05-12 |
| 2021-12-31 | $2.79M 10-K · filed 2022-03-10 |
| 2021-09-30 | $3.12M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $5.36M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $5.05M 10-Q · filed 2021-05-11 |
| 2020-12-31 | $8.23M 10-K · filed 2021-03-11 |
| 2020-09-30 | $6.41M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $11.57M 10-Q · filed 2020-08-20 |